|
Teva Announces Approval Of Deferoxamine Mesylate For Injection USP |
|
|
|
03 Apr 2006 |
JERUSALEM, Israel | Apr 02, 2006 | Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company’s ANDA for Deferoxamine Mesylate for Injection USP, 500 mg/vial and 2 g/vial. Shipment of this product will begin immediately. Teva’s Deferoxamine Mesylate for Injection is the AP-rated generic equivalent of Novartis’ Desferal® for Injection, a product indicated for acute treatment of iron intoxication and chronic iron overload due to transfusion-dependent anemias. Total annual sales of Deferoxamine Mesylate for Injection are approximately $43 million.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90% of Teva’s sales are in North America and Europe.
SOURCE: Teva Pharmaceutical Industries Ltd |
